Aligos Therapeutics Inc (ALGS)vsargenx NV ADR (ARGX)
ALGS
Aligos Therapeutics Inc
$5.17
+9.07%
HEALTHCARE · Cap: $30.35M
ARGX
argenx NV ADR
$891.76
+1.05%
HEALTHCARE · Cap: $54.94B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 18669% more annual revenue ($5.92B vs $31.52M). ARGX leads profitability with a 31.7% profit margin vs -241.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ALGS
Hold41
out of 100
Grade: D
ARGX
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+87.5%
Fair Value
$59.86
Current Price
$5.17
$54.69 discount
Margin of Safety
+67.5%
Fair Value
$2566.94
Current Price
$891.76
$1675.18 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 2779.0% year-over-year
Conservative balance sheet, low leverage
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 36.3%
Revenue surging 52.1% year-over-year
Earnings expanding 50.6% YoY
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -284.1% — below average capital efficiency
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 165.8x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ALGS
The strongest argument for ALGS centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 2779.0% demonstrates continued momentum.
Bull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.7% and operating margin at 36.3%. Revenue growth of 52.1% demonstrates continued momentum.
Bear Case : ALGS
The primary concerns for ALGS are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
ALGS profiles as a hypergrowth stock while ARGX is a growth play — different risk/reward profiles.
ALGS carries more volatility with a beta of 2.36 — expect wider price swings.
ALGS is growing revenue faster at 2779.0% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (73/100 vs 41/100), backed by strong 31.7% margins and 52.1% revenue growth. ALGS offers better value entry with a 87.5% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aligos Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing novel therapies to address unmet medical needs in viral and liver diseases. The company is headquartered in South San Francisco, California.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?